MétaCan
Menu
← Back to cohort
Record W4386005974

Neuro-ophthalmic Complications of Immune Checkpoint Inhibitors: A Systematic Review

2020· review· en· W4386005974 on OpenAlexaboutno aff
Yu CW, Yau M, Natalie Mezey, Ishraq Joarder, Micieli JA

Bibliographic record

VenueDOAJ (DOAJ: Directory of Open Access Journals) · 2020
Typereview
Languageen
FieldMedicine
TopicMultiple Myeloma Research and Treatments
Canadian institutionsnot available
Fundersnot available
KeywordsMedicineImmune checkpointImmune systemImmunologyImmunotherapy
DOInot available

Abstract

fetched live from OpenAlex

Caberry W Yu,1 Matthew Yau,2 Natalie Mezey,1 Ishraq Joarder,3 Jonathan A Micieli4,5 1Faculty of Medicine, Queen’s University, Kingston, Canada; 2Faculty of Medicine, University of Toronto, Toronto, Canada; 3Faculty of Science, University of Toronto, Scarborough, Ontario, Canada; 4Department of Ophthalmology and Vision Sciences and Division of Neurology, Department of Medicine, University of Toronto, Toronto, Canada; 5Kensington Vision and Research Centre, Toronto, CanadaCorrespondence: Jonathan A MicieliKensington Vision and Research Centre, 340 College Street, Suite 501, Toronto, Ontario M5T 3A9, CanadaTel +1(416) 928-1335Fax +1(416) 928-5075Email jmicieli@kensingtonhealth.orgObjective: Immune checkpoint inhibitors (ICIs) are novel cancer therapies that may be associated with immune-related adverse events (IRAEs) and come to the attention of neuro-ophthalmologists. This systematic review aims to synthesize the reported ICI-associated IRAEs relevant to neuro-ophthalmologists to help in the diagnosis and management of these conditions.Methods: A systematic review of the literature indexed by MEDLINE, Embase, CENTRAL, and Web of Science databases was searched from inception to May 2020. Reporting followed the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) guidelines. Primary studies on ICIs and neuro-ophthalmic complications were included. Outcomes included number of cases and incidence of neuro-ophthalmic IRAEs.Results: Neuro-ophthalmic complications of ICIs occurred in 0.46% of patients undergoing ICI and may affect the afferent and efferent visual systems. Afferent complications include optic neuritis (12.8%), neuroretinitis (0.9%), and giant cell arteritis (3.7%). Efferent complications include myasthenia gravis (MG) (45.0%), thyroid-like eye disease (11.9%), orbital myositis (13.8%), general myositis with ptosis (7.3%), internuclear ophthalmoplegia (0.9%), opsoclonus-myoclonus-ataxia syndrome (0.9%), and oculomotor nerve palsy (0.9%). Pembrolizumab was the most common causative agent for neuro-ophthalmic complications (32.1%). Mortality was highest for MG (19.8%). Most patients (79.8%) experienced improvement or complete resolution of neuro-ophthalmic symptoms due to cessation of ICI and immunosuppression with systemic corticosteroids.Conclusion: While incidence of neuro-ophthalmic IRAEs is low, clinicians involved in the care of cancer patients must be aware of their presentation to facilitate prompt recognition and management. Collaboration between oncology and neuro-ophthalmology teams is required to effectively manage patients and reduce morbidity and mortality.Keywords: immune checkpoint inhibitors, cancer immunotherapy, CTLA-4 inhibitors, PD-1 inhibitors, PD-L1 inhibitors

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.005
metaresearch head score (Gemma)0.026
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Systematic review · Consensus signal: Systematic review
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.011
Threshold uncertainty score0.028

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0050.026
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0080.008
Bibliometrics0.0090.011
Science and technology studies0.0010.001
Scholarly communication0.0020.002
Open science0.0020.002
Research integrity0.0020.001
Insufficient payload (model declined to judge)0.0040.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.393
GPT teacher head0.601
Teacher spread0.208 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designSystematic review
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations3
Published2020
Admission routes1
Has abstractyes

Explore more

Same venueDOAJ (DOAJ: Directory of Open Access Journals)→Same topicMultiple Myeloma Research and Treatments→French-language works237,207→